Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy
Authors
Keywords
-
Journal
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
Volume 102, Issue 9, Pages 3216-3228
Publisher
Wiley
Online
2013-10-26
DOI
10.1002/jbm.a.34992
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polymeric micelles for siRNA delivery
- (2015) A. Falamarzian et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Effective down-regulation of Breast Cancer Resistance Protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers
- (2012) Hamidreza Montazeri Aliabadi et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Effects of STAT3 Gene Silencing and Rapamycin on Apoptosis in Hepatocarcinoma Cells
- (2012) Yi Zhang et al. International Journal of Medical Sciences
- Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
- (2012) Yanti Octavia et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Cosmomycin C inhibits signal transducer and activator of transcription 3 (STAT3) pathways in MDA-MB-468 breast cancer cell
- (2011) Jihoon Kim et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Impact of Lipid Substitution on Assembly and Delivery of siRNA by Cationic Polymers
- (2011) Hamidreza Montazeri Aliabadi et al. MACROMOLECULAR BIOSCIENCE
- B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
- (2011) H. Liu et al. MOLECULAR CANCER THERAPEUTICS
- RNA Interference and Cancer Therapy
- (2011) Zhaohui Wang et al. PHARMACEUTICAL RESEARCH
- Viral vector-mediated RNA interference
- (2010) Linda B Couto et al. CURRENT OPINION IN PHARMACOLOGY
- Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung
- (2010) Melanie Günther et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Efficient and targeted delivery of siRNA in vivo
- (2010) Min Suk Shim et al. FEBS Journal
- Novel self-associating poly(ethylene oxide)-b-poly(ɛ-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery
- (2010) Mostafa Shahin et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Lipid and hydrophobic modification of cationic carriers on route to superior gene vectors
- (2010) Vanessa Incani et al. Soft Matter
- The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine
- (2009) Aws Alshamsan et al. BIOMATERIALS
- Reciprocal Effects of STAT5 and STAT3 in Breast Cancer
- (2009) S. R. Walker et al. MOLECULAR CANCER RESEARCH
- Aliphatic Lipid Substitution on 2 kDa Polyethylenimine Improves Plasmid Delivery and Transgene Expression
- (2009) Artphop Neamnark et al. MOLECULAR PHARMACEUTICS
- Strategies for targeted nonviral delivery of siRNAs in vivo
- (2009) Sang-Soo Kim et al. TRENDS IN MOLECULAR MEDICINE
- Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery
- (2008) Xiao-Bing Xiong et al. BIOMATERIALS
- Targeting STAT3 in cancer: how successful are we?
- (2008) Peibin Yue et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started